HER2-positive Breast Cancer Project Initiated by Investigators
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study will assess the objective response rate (ORR), safety, progression-free survival
(PFS) , overall survival (OS), 6-month survival rate, 12-month survival rate, 18-month
survival rate, 24-month survival rate, disease control rate (DCR), clinical benefit rate
(CBR), duration of response (DOR) and Time to Response (TTR). Injection of A166 for
HER2-positive patients with refractory unresectable locally advanced or metastatic breast
cancer who have failed previous ADC drug therapy.